VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel small molecule product candidates targeting Toll-like receptor 8 (TLR8) for cancer.

from http://www.ventirx.com/about/index.html

Patents 141show all

  • 53
    A61K - Preparations for medical, dental, or toilet purposes
  • 40
    C07D - Heterocyclic compounds
  • 15
    B82Y - Specific uses or applications of nanostructures
  • 14
    C07K - Peptides

Clinical Trials 1show all

1Phase 1/Phase 2

SEC Filings show all


4
D

Contact Information

1191 Second Avenue, Suite 1105
Seattle, WA 98101
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$104,502,51411-502014-09-23Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2014-09-23$50,602,514Series BARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, MedImmune Ventures, Celgene
2006-01-01$2,300,000Seed
2010-01-13$25,000,000Series AMedImmune VenturesARCH Venture Partners, Frazier Healthcare Partners, Domain Associates
2007-03-06$26,600,000Series AFrazier Healthcare PartnersDomain Associates, ARCH Venture Partners

SEC Form D Funding Events

DateOfferedSoldType
2014-09-30$15,000,000$15,000,000Equity, Option to Acquire, Security to be Acquired
2014-09-23$53,102,414$50,602,514Equity
2012-03-08$25,000,002$18,750,001Equity
2007-03-22Unknown Unknown Other (Paper Filing)

Key Executives

  • Robert M. Hershberg, M.D., Ph.D.
    Executive Officer, Director
  • Patrick Heron
    Director
  • Nicole Vitullo
    Director
  • Steven Gillis, Ph.D.
    Director
  • Elliot Grossbard, M.D.
    Director
  • Atul Saran
    Director
  • Kent Snyder
    Director
  • Ron Laufer
    Director
  • Kathleen Fanning
    Executive Officer